SynthesisScientific reports2025
Arrhythmic risk in mitral valve prolapse with mitral annular disjunction: meta-analysis of longitudinal studies.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Arrhythmic Mitral Valve Prolapse as a Regional Stretch-Induced Cardiomyopathy with Fibro-Inflammatory Signature: A Conceptual Review.Journal of cardiovascular development and disease · 2026Review
- From Modified Haller Index to a Novel Patented Anatomical Measurement Device: Engineering Development, Validation, and Clinical Applications of Non-Invasive Thoracic Morphometry.Bioengineering (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitral valve prolapse (MVP) is frequently associated with mitral annular disjunction (MAD). Although numerous studies and emerging consensus suggest an arrhythmogenic role for MAD, there is a lack of large-scale meta-analyses of longitudinal studies to definitively confirm this association. We aim to evaluate the longitudinal arrhythmic risk in patients with MVP and MAD. We systematically searched PubMed, Cochrane Library, and Scopus for longitudinal studies assessing arrhythmic risk in MVP patients with MAD, from inception to May 2025. Diagnostic performance measures (sensitivity, specificity, diagnostic odds ratio, positive/negative predictive values) were pooled. Odds ratios (OR) with 95% confidence intervals (CI) were calculated using a DerSimonian and Laird random-effects model. Heterogeneity was assessed via I² and Kendall's tau. The summary receiver operating characteristic (sROC) curve and area under the curve (AUC) were estimated using Martínez-Camblor's method. Six studies, including 1880 MVP patients, 751 with MAD, and 1129 without, were analyzed. There was no unique method to diagnose MAD. The pooled prevalence of MAD was 36% (95% CI 22-53%). MAD was associated with increased arrhythmic risk (OR: 2.60; 95% CI: 1.99-3.38, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.